SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH M impact

US FDA Declines to Approve Summit’s Lung Cancer Drug

Summit shares dropped after the FDA declined to approve its lung cancer drug.

SMMT

Story updates

03:24:42 PM UTC
SquawkNews
By Mariam SunnyShares of Summit Therapeutics NASDAQ:SMMT fell 14% on Monday after the US Food and Drug Administration declined to approve its experimental lung cancer drug ivonescimab.The regulator on Sunday cited the drug's failure to achieve statistically significant overall survival benefit in a…

Related stories